PVLA
Palvella Therapeutics, Inc.
$151.97
+2.29 (+1.53%)
At close · Jul 15
Market Cap
$2.18B
Shares
14,342,844
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$151.97
Open$146.77
Day$144.99–154.68
52W$26.78–161.38
Avg vol 30d315K
Short int2.4M · 16.5% float · 6.3d
Short vol87%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+45%
above
Price vs 50-day avg
+22%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
93%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+30%
trailing
6-month return
+62%
trailing
YTD return
+45%
this year
Relative strength
+52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $124 › 200d $105 — 50d above 200d
Institutional flow
Accumulating
4 of 182 funds reported for Jun 30 · net +72 sh shares · +2 new
Insider flow
Distributing
Net -$475.6K over 90 days · 100% sells
Short interest
Rising
16.50% of float · ▲ +13.9% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
182 holders — near 1-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
EPS growth
+53%
Y/Y
Free cash flow
$-25.2M
Balance sheet
$58.0M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+45%
Bullish
Price vs 50-day avg
+22%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $124 › 200d $105 — 50d above 200d
Institutional flow
Accumulating
4 of 182 funds reported for Jun 30 · net +72 sh shares · +2 new
Insider flow
Distributing
Net -$475.6K over 90 days · 100% sells
Short interest
Rising
16.50% of float · ▲ +13.9% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
182 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $27
Now $152 · 93%
52-wk high $161
vs 200-day avg +45%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PVLA
this stock
Palvella Therapeutics, Inc.
|
$2.18B | +45.2% | +65.3% | — | 16.5% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.66B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.96B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PVLA | +4.7% | +30.4% | +61.8% | -0.6% | +45.2% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +3.4% | +30.6% | +51.7% | -1.6% | +34.5% |